2LALERG is developed by Labo'Life.

What development phase is 2LALERG in?

2LALERG is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

2LALERG

Labo'Life · FDA-approved active Small molecule Quality 4/100

2LALERG, marketed by Labo'Life, is a small molecule with an unknown mechanism of action, currently holding a position in the pharmaceutical market without specified primary indications or revenue data. The key strength of 2LALERG lies in its composition patent, which is set to expire in 2028, providing a period of exclusivity. The primary risk is the lack of detailed clinical trial results and clear primary indications, which may limit its market acceptance and competitive positioning.

At a glance

Generic name	2LALERG
Also known as	Immunotherapy
Sponsor	Labo'Life
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy of 2LALERG (Homeopathic Drug) in Allergic Rhinitis Related to Grass Pollen (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results